GoodRx Holdings Capital Expenditures (CapEx) Growth & History (GDRX)
GoodRx Holdings's capital expenditures (capex) was $3.5M for fiscal 2025.
View full GoodRx Holdings company overviewGoodRx Holdings annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.5M | $2.3M | +183.95% |
| 2024 | 2024-12-31 | $1.2M | $197,000 | +18.89% |
| 2023 | 2023-12-31 | $1.0M | −$2.9M | −73.71% |
| 2022 | 2022-12-31 | $4.0M | −$604,000 | −13.21% |
| 2021 | 2021-12-31 | $4.6M | −$16.0M | −77.76% |
| 2020 | 2020-12-31 | $20.6M | $19.1M | +1342.32% |
| 2019 | 2019-12-31 | $1.4M | $621,000 | +77.24% |
| 2018 | 2018-12-31 | $804,000 | — | — |
GoodRx Holdings quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $362,000 | −$28,000 | −7.18% |
| Q1 2026 | 2026-03-31 | $1.1M | $994,000 | +700.00% |
| Q4 2025 | 2025-12-31 | $1.2M | $1.1M | +666.05% |
| Q3 2025 | 2025-09-30 | $1.7M | $1.3M | +333.75% |
| Q2 2025 | 2025-06-30 | $390,000 | $122,000 | +45.52% |
| Q1 2025 | 2025-03-31 | $142,000 | −$265,000 | −65.11% |
| Q4 2024 | 2024-12-31 | $162,000 | −$247,000 | −60.39% |
| Q3 2024 | 2024-09-30 | $403,000 | $209,000 | +107.73% |
| Q2 2024 | 2024-06-30 | $268,000 | −$24,000 | −8.22% |
| Q1 2024 | 2024-03-31 | $407,000 | $259,000 | +175.00% |
| Q4 2023 | 2023-12-31 | $409,000 | $259,000 | +172.67% |
| Q3 2023 | 2023-09-30 | $194,000 | −$451,000 | −69.92% |
| Q2 2023 | 2023-06-30 | $292,000 | −$1.1M | −79.67% |
| Q1 2023 | 2023-03-31 | $148,000 | −$1.6M | −91.47% |
| Q4 2022 | 2022-12-31 | $150,000 | −$657,000 | −81.41% |
| Q3 2022 | 2022-09-30 | $645,000 | −$61,000 | −8.64% |
| Q2 2022 | 2022-06-30 | $1.4M | $1.1M | +318.66% |
| Q1 2022 | 2022-03-31 | $1.7M | −$979,000 | −36.06% |
| Q4 2021 | 2021-12-31 | $807,000 | −$4.1M | −83.44% |
| Q3 2021 | 2021-09-30 | $706,000 | −$13.2M | −94.92% |
| Q2 2021 | 2021-06-30 | $343,000 | −$762,000 | −68.96% |
| Q1 2021 | 2021-03-31 | $2.7M | $2.0M | +302.82% |
| Q4 2020 | 2020-12-31 | $4.9M | — | — |
| Q3 2020 | 2020-09-30 | $13.9M | — | — |
| Q2 2020 | 2020-06-30 | $1.1M | — | — |
| Q1 2020 | 2020-03-31 | $674,000 | — | — |
GoodRx Holdings capital expenditures (capex) trends
Over the last five fiscal years, GoodRx Holdings's capital expenditures (capex) decreased from $20.6M to $3.5M, a change of −$17.0M. The latest reported quarter, Q2 2026, shows $362,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review GoodRx Holdings source filings ↗